Tags

Type your tag names separated by a space and hit enter

Author Correction: High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics.
Nat Biotechnol. 2020 06; 38(6):756.NBio

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Gérard A
HiFiBiO Therapeutics SAS, Paris, France.
Woolfe A
HiFiBiO Therapeutics SAS, Paris, France.
Mottet G
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.
Reichen M
HiFiBiO Therapeutics SAS, Paris, France.
Castrillon C
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France. École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France. Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
Menrath V
HiFiBiO Therapeutics SAS, Paris, France.
Ellouze S
HiFiBiO Therapeutics SAS, Paris, France.
Poitou A
HiFiBiO Therapeutics SAS, Paris, France.
Doineau R
HiFiBiO Therapeutics SAS, Paris, France. École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France. Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France. Institute for Integrative Nanosciences, Leibniz IFW Dresden e.V., Dresden, Germany.
Briseno-Roa L
HiFiBiO Therapeutics SAS, Paris, France. Medetia Pharma, Institut Imagine, Paris, France.
Canales-Herrerias P
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France. École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France. Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
Mary P
HiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Rose G
HiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Ortega C
HiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Delincé M
HiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Essono S
HiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Jia B
Pfizer, Cambridge, MA, USA. Abbvie Bioresearch Center, Worcester, MA, USA.
Iannascoli B
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.
Richard-Le Goff O
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.
Kumar R
HiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Stewart SN
HiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Pousse Y
HiFiBiO Therapeutics SAS, Paris, France.
Shen B
HiFiBiO Therapeutics SAS, Paris, France.
Grosselin K
HiFiBiO Therapeutics SAS, Paris, France. Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
Saudemont B
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France. Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
Sautel-Caillé A
Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
Godina A
Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
McNamara S
HiFiBiO Therapeutics SAS, Paris, France.
Eyer K
Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France. Laboratory for Functional Immune Repertoire Analysis, Institute of Pharmaceutical Sciences, D-CHAB, ETH Zürich, Zurich, Switzerland.
Millot GA
Institut Pasteur, Hub Bioinformatique et Biostatistique, C3BI, USR 3756 IP CNRS, Paris, France.
Baudry J
Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
England P
Plateforme de Biophysique Moléculaire, Institut Pasteur, CNRS UMR3528, Paris, France. Centre d'Innovation et de Technologie, Plateforme de Biophysique des Macromolecules et de leurs Interactions, Institut Pasteur, Paris, France.
Nizak C
Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
Jensen A
HiFiBiO Therapeutics SAS, Paris, France. Lundbeck A/S, Valby, Denmark.
Griffiths AD
Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France. andrew.griffiths@espci.fr.
Bruhns P
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France. pierre.bruhns@pasteur.fr.
Brenan C
HiFiBiO Therapeutics SAS, Paris, France. c.brenan@1cell-bio.com. HiFiBiO Therapeutics Inc., Cambridge, MA, USA. c.brenan@1cell-bio.com. 1CellBiO Inc., Watertown, MA, USA. c.brenan@1cell-bio.com.

Pub Type(s)

Journal Article
Published Erratum

Language

eng

PubMed ID

32444853

Citation

Gérard, Annabelle, et al. "Author Correction: High-throughput Single-cell Activity-based Screening and Sequencing of Antibodies Using Droplet Microfluidics." Nature Biotechnology, vol. 38, no. 6, 2020, p. 756.
Gérard A, Woolfe A, Mottet G, et al. Author Correction: High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. Nat Biotechnol. 2020;38(6):756.
Gérard, A., Woolfe, A., Mottet, G., Reichen, M., Castrillon, C., Menrath, V., Ellouze, S., Poitou, A., Doineau, R., Briseno-Roa, L., Canales-Herrerias, P., Mary, P., Rose, G., Ortega, C., Delincé, M., Essono, S., Jia, B., Iannascoli, B., Richard-Le Goff, O., ... Brenan, C. (2020). Author Correction: High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. Nature Biotechnology, 38(6), 756. https://doi.org/10.1038/s41587-020-0563-7
Gérard A, et al. Author Correction: High-throughput Single-cell Activity-based Screening and Sequencing of Antibodies Using Droplet Microfluidics. Nat Biotechnol. 2020;38(6):756. PubMed PMID: 32444853.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Author Correction: High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. AU - Gérard,Annabelle, AU - Woolfe,Adam, AU - Mottet,Guillaume, AU - Reichen,Marcel, AU - Castrillon,Carlos, AU - Menrath,Vera, AU - Ellouze,Sami, AU - Poitou,Adeline, AU - Doineau,Raphaël, AU - Briseno-Roa,Luis, AU - Canales-Herrerias,Pablo, AU - Mary,Pascaline, AU - Rose,Gregory, AU - Ortega,Charina, AU - Delincé,Matthieu, AU - Essono,Sosthene, AU - Jia,Bin, AU - Iannascoli,Bruno, AU - Richard-Le Goff,Odile, AU - Kumar,Roshan, AU - Stewart,Samantha N, AU - Pousse,Yannick, AU - Shen,Bingqing, AU - Grosselin,Kevin, AU - Saudemont,Baptiste, AU - Sautel-Caillé,Antoine, AU - Godina,Alexei, AU - McNamara,Scott, AU - Eyer,Klaus, AU - Millot,Gaël A, AU - Baudry,Jean, AU - England,Patrick, AU - Nizak,Clément, AU - Jensen,Allan, AU - Griffiths,Andrew D, AU - Bruhns,Pierre, AU - Brenan,Colin, PY - 2020/5/24/pubmed PY - 2020/5/24/medline PY - 2020/5/24/entrez SP - 756 EP - 756 JF - Nature biotechnology JO - Nat Biotechnol VL - 38 IS - 6 N2 - An amendment to this paper has been published and can be accessed via a link at the top of the paper. SN - 1546-1696 UR - https://www.unboundmedicine.com/medline/citation/32444853/Author_Correction:_High_throughput_single_cell_activity_based_screening_and_sequencing_of_antibodies_using_droplet_microfluidics_ DB - PRIME DP - Unbound Medicine ER -